Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain
- Irimia, P.
- Santos-Lasaosa, S.
- García Bujalance, L.
- Ramos Pinazo, L.
- Rubio-Rodríguez, D.
- Rubio-Terrés, C.
ISSN: 1744-8379, 1473-7167
Année de publication: 2021
Volumen: 21
Número: 2
Pages: 285-297
Type: Article